

GENERAL INFORMATION

REGISTRATION

Registration is free of charge.

You may register for IN-PERSON OR ONLINE-ONLY ACCESS

<https://www.events-communication.com/event/lungcancer2025/>

<https://www.lungcancer-milan.com/>

CONGRESS VENUE

Aula Magna - Fondazione IRCCS Istituto Nazionale Tumori

Via Giacomo Venezian, 1 20133 Milan (Italy)

VIRTUAL CONFERENCE

<https://www.events-fad.com/>

OFFICIAL LANGUAGE AND TIME

The official language is English. The official Time is Central European Summer Time (CEST), UTC +2

C.M.E. CREDITS

CME accreditation (valid for Italian participants only) for: Medical Doctor, Chemist, Pharmacist, Biologist, Physician, Nurse.

Italian CME credits will be granted to those participants who attend at least 90% of scientific works, 11 in the questionnaire assessment of perceived quality and duly 11 in the evaluation questionnaires answering correctly 75% of the questions.

SCIENTIFIC PROVIDER AND CONGRESS ORGANIZER

E'
EVENTS
CONGRESS & COMMUNICATION

Events srl

Via L. Lotto 9, 60019 Senigallia (AN)
Ph. +39 071 7930220 Fax. +39 071 9252094
www.events-communication.com
segreteria@events-communication.com



DECEMBER 15th - MILAN, ITALY & ONLINE

SCIENTIFIC PROGRAM

10:30 Registration

11:00 Welcome and introduction

Giuseppe Lo Russo

Gustavo Galmozzi, *President - Fondazione IRCCS Istituto Nazionale dei Tumori (invited)*

Maria Teresa Montella, *General Director Fondazione IRCCS Istituto Nazionale dei Tumori (invited)*

Giovanni Apolone, *Scientific Director, Fondazione IRCCS Istituto Nazionale dei Tumori (invited)*

Filippo de Braud *Director Dpt. of Oncology and Hemato-Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori (invited)*

1 SESSION

NSCLC EARLY AND LOCALLY
ADVANCED DISEASE

Chairs: **R. Ferrara, M. Imbimbo, A. Prelaj**

11:10 New surgical advances
Piergiorgio Solli

11:30 Adjuvant ,Neoadjuvant and Peri-operative
approach in wt NSCLC patients
Tina Cascone

11:50 Medical treatment of early stages
in oncongene addicted patients
Jarushka Naidoo

12:10 Not-resectable locally advance disease:
the present and the future
Andrea Riccardo Filippi

12:30 Round Table and Questions
All

13:00 LUNCH

2 SESSION

NSCLC ADVANCED DISEASE:
WT AND KRAS MUTATED

Chairs: **M. Brambilla, M. Meazza-Prina,
M. Occhipinti**

14:00 IO monotherapy and IO combinations
in special populations
Marina Chiara Garassino

14:20 IO beyond progression,
IO re-Challenge and the optimal
duration of IO treatment
Helena Linardou

14:40 New Strategies for patients progressive to IO
Benjamin Besse

15:00 K-RAS mutated patients:
a new world opens up
Martin Reck

15:20 Round Table and Questions
All

15:50 COFFEE BREACK

3 SESSION

NSCLC ONCOGENE ADDICTED
ADVANCED DISEASE

Chairs: **G. Corrao, C. Proto, G. Viscardi,**

16:00 Liquid biopsy:
the present and the future
Umberto Malapelle

16:20 New perspectives for EGFR
mutated patients
Luis Paz Ares

16:40 Current treatment algorithms for BRAF,
MET, HER2 positive patients
Eriqueta Felip

17:00 Updates for ALK, ROS1, RET, NTRK
positive patients
David Carbone

17:20 Round Table and Questions
All

SPECIAL LECTURES A LOOK BEYOND NSCLC

Chairs: **T. Beninato, L. Mazzeo, D. Signorelli**

17:50 SCLC the state of the art
Stephen V Liu

18:10 Thymic Neoplasms Finally
something new?
Joordi Remon Masip

18:30 Pleural Mesothelioma updates
Giovanni Ceresoli

18:50 Conclusions remarks
Giuseppe Lo Russo

19:00 COCKTAIL

"Let's break the ice
in lung cancer"



OVERVIEW

The treatment of lung cancer is evolving rapidly. Our annual meeting provides an update on data from major national and international conferences, allowing experts and participants to discuss the latest findings, put them in context and really understand how they affect our daily practice. Participants will have the opportunity to engage with faculty members who will share their views on the main controversies surrounding the management of lung cancer. Leading experts in the treatment of lung cancer will share their ideas and knowledge with congress participants with the ultimate goal of mutual enrichment.

PRESIDENT OF THE CONFERENCE

GIUSEPPE LO RUSSO

*Thoracic Unit - Medical Oncology,
Fondazione IRCCS Istituto Nazionale dei Tumori,
Milano IT*

FACULTY

Teresa Beninato, Thoracic Unit, Medical Oncology,
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

Benjamin Besse, Medical Oncology Université
Paris-Saclay, Clinical Research at Gustave Roussy Institut,
Villejuif FR

Marta Brambilla, Thoracic Unit, Medical Oncology,
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

David Carbone, Professor of Internal Medicine, Director
of the James Thoracic Oncology Center at the OSUMC
and holds the Barbara J. Bonner Chair in Lung Research,
Ohio USA

Tina Cascone, Dpt. Thoracic/Head and Neck Medical
Oncology, Division of Cancer Medicine, University of
Texas MD Anderson Cancer Center, Houston, TX USA

Giovanni Luca Ceresoli, Medical Oncology Humanitas
Gavazzeni Bergamo

Giulia Corrao, Thoracic Unit, Medical Oncology,
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

Enriqueta Felip, Font Lung Cancer Unit, Oncology Dpt.
Vall d'Hebron University Hospital Barcelona, ES

Roberto Ferrara, Thoracic Oncology and Molecular
Immunology IRCCS Ospedale San Raffaele, Milano IT

Andrea Riccardo Filippi, Associate Professor in
Radiation Oncology at the University of Milan and Head
of Radiotherapy, Istituto Nazionale Tumori, Milano IT

Marina Chiara Garassino, Thoracic Oncology Program,
University of Chicago, IL USA

Martina Imbimbo, Ente Ospedaliero Cantonale,
Bellinzona SW

Helena Linardou, Oncology Dpt. and Comprehensive
Clinical Trials Center of Metropolitan Hospital, Athens,
GR

Stephen V Liu, Medical Oncologist, Thoracic Oncology,
Head of Developmental Therapeutics at Georgetown
Lombardi Comprehensive Cancer Center, Washington,
DC USA

Giuseppe Lo Russo, Thoracic Unit - Medical
Oncology, Fondazione IRCCS Istituto Nazionale dei
Tumori, Milano IT

Umberto Malapelle, Dpt. of Public Health, Università
Federico II di Napoli IT

Laura Mazzeo, Thoracic Unit, Medical Oncology,
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

Marco Meazza Prina, Thoracic Unit, Medical
Oncology, Fondazione IRCCS Istituto Nazionale dei
Tumori, Milano IT

Jarushka Naidoo, Beaumont Hospital Dublin, IE

Mario Occhipinti, Thoracic Unit, Medical Oncology,
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

Luis Paz Ares, Medical Oncology Dpt. Hospital
Universitario 12 de Octubre, Universidad Complutense
de Madrid, Lung Cancer Unit National Oncology
Research Center, Madrid ES

Arsela Prelaj, Thoracic Unit, Medical Oncology,
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

Claudia Proto, Thoracic Unit, Medical Oncology,
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano IT

Martin Reck, Dpt. of Thoracic Oncology, Lung Clinic
Grosshansdorf, DE

Jordi Remon Masip, Dpt. of Cancer Medicine, Gustave
Roussy, Villejuif, FR

Diego Signorelli, Niguarda Cancer Center, Grande
Ospedale Metropolitano Niguarda, Milano IT

Piergiorgio Solli, Dpt. of Thoracic Surgery, Fondazione
IRCCS Istituto Nazionale dei Tumori, Milano IT

Giuseppe Viscardi, Medical Oncology, AO Monaldi
Cotugno Cto, Università degli Studi della Campania
Luigi Vanvitelli, Napoli IT